

Diabetes in Individuals with Tuberous Sclerosis Complex Treated with MTOR Inhibitors

Evelyn Joy*

Department of Neurology, University of North Texas, Denton, Texas

Corresponding Author*

Evelyn Joy
Department of Neurology,
University of North Texas, Denton,
Texas
E-mail: Evelynjoy@gmail.com

Copyright: © 2021 Joy E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 04 Apr 2021; **Accepted** 21 Apr 2021; **Published** 28 Apr 2021

Abstract

Tuberous sclerosis complex (TSC) is a genetic disorder that is manifested in multiple body systems. Diabetes mellitus is a disorder of carbohydrate metabolism characterized by impaired ability of the body to produce or respond to insulin and thereby maintain proper levels of glucose in the blood. mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases (PIKKs).

Introduction

Tuberous sclerosis complex (TSC) could be a hereditary condition that's manifested in multiple body systems. Initiation of An mTOR inhibitor, either everolimus or sirolimus, are now routinely prescribed for multiple clinical manifestations of TSC, together with subependymal giant cell astrocytoma and epilepsy. These medication are usually well tolerated. Side effects

previously identified in well-designed clinical trials tend to be mild in severity and are readily manageable. Regulatory approvals for; the management of TSC have expanded and use of everolimus and sirolimus; clinically, enlarging clinician experience and enabling identification of additional; potential treatment-related effects that are rare than could be identified or recognized; in earlier clinical trials.

The medical case reports of clinical patients from our TSC center who were treated with an mTOR inhibitor and later on developed diabetes mellitus (DM) were analyzed and compared to those who were not treated with an mTORi. Eight received detailed analysis, including lab results, concomitant medications and body mass indices.

Of the 1576, 4% taking an mTORi developed diabetes compared to 0.6% of those not on mTORi showing that a significant interaction between DM and mTORi (Chi Square= 18.1, $p < 0.001$).

Discussion

The semipermanent use of mTOR inhibitors in TSC could contribute to polygenic disease risk. Early detection is important in management. Future studies would be necessary to demonstrate a causative relationship, however clinicians ought to remember of this potential implication once educating families, initiating and observance in progress treatment. The semipermanent use of mTOR inhibitors in TSC could contribute to polygenic disease risk. Early detection is important in management. Future studies would be necessary to demonstrate a causative relationship, however clinicians ought to remember of this potential implication once educating families.

References

1. Saxton, R.A., & Sabatini, D.M. "mTOR Signaling in Growth, Metabolism, and Disease." *Cell*. 168 (2017): 960-976.
2. Franz D.N., et al. "Long-term use of everolimus in patients with tuberous sclerosis complex: Final results from the EXIST-1 study." *PLoS ONE*. 11(2016): 1-113.